新型药物时代慢性淋巴细胞白血病的异基因干细胞移植
这项多中心回顾性队列研究分析了65例接受过至少一种新型药物(NA)后行异基因造血干细胞移植(alloHCT)的慢性淋巴细胞白血病(CLL)患者,24个月无进展生存率63%、总生存率81%、非复发死亡率13%、复发率27%,移植前NA暴露不影响移植安全性和生存结局,alloHCT仍是可行的长期疾病控制策略。
要点
- 65例CLL患者接受≥1种NA后行alloHCT,24个月PFS为63%、OS为81%。
- 移植前NA暴露、NA种类数及末线NA类型均不影响PFS和OS。
- 造血干细胞移植特异性合并症指数独立预测PFS。
核心结论
- alloHCT仍是可克服CLL不良特征的可行长期疾病控制策略,既往NA暴露不影响移植安全性,生存结局与NA数量、既往化疗免疫治疗暴露或末线NA类型无关。
- 决定是否行alloHCT时应考虑合并症及对剩余治疗方案的预期反应。
研究设计与样本
- 多中心回顾性队列研究,纳入65例接受过至少1种NA后行alloHCT的CLL患者。
- 分析基线疾病与移植特征、alloHCT前治疗、移植结局、alloHCT后治疗及生存结局。
- 采用单变量和多变量分析评估alloHCT前因素与无进展生存期(PFS)的关联。
主要发现
- 因CLL移植的患者24个月PFS为63%、OS为81%、非复发死亡率为13%、复发率为27%。
- III-IV级急性移植物抗宿主病(GVHD)第+100天累积发生率为24%,中重度GVHD发生率为27%。
- 不良风险疾病特征、既往NA暴露、完全缓解 vs 部分缓解及移植特征均未独立关联PFS。
- 造血干细胞移植特异性合并症指数独立预测PFS。
- 接受NA vs NA联合化疗免疫治疗、1种 vs ≥2种NA、伊布替尼 vs 维奈克拉作为alloHCT前末线治疗,均未影响PFS和OS。
关键数值与推荐
- 24个月PFS为63%、OS为81%、非复发死亡率为13%、复发率为27%。
- III-IV级急性GVHD第+100天累积发生率为24%,中重度GVHD发生率为27%。
- 造血干细胞移植特异性合并症指数独立预测PFS。
临床怎么用
- 既往NA暴露不影响alloHCT安全性,生存结局与NA数量、既往化疗免疫治疗暴露或末线NA类型无关。
- 决定是否行alloHCT时应考虑合并症及对剩余治疗方案的预期反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although novel agents (NAs) have improved outcomes for patients with chronic lymphocytic leukemia (CLL), a subset will progress through all available NAs. Understanding outcomes for potentially curative modalities including allogeneic hematopoietic stem cell transplantation (alloHCT) following NA therapy is critical while devising treatment sequences aimed at long-term disease control. In this multicenter, retrospective cohort study, we examined 65 patients with CLL who underwent alloHCT following exposure to ≥1 NA, including baseline disease and transplant characteristics, treatment preceding alloHCT, transplant outcomes, treatment following alloHCT, and survival outcomes. Univariable and multivariable analyses evaluated associations between pre-alloHCT factors and progression-free survival (PFS). Twenty-four-month PFS, overall survival (OS), nonrelapse mortality, and relapse incidence were 63%, 81%, 13%, and 27% among patients transplanted for CLL. Day +100 cumulative incidence of grade III-IV acute graft-vs-host disease (GVHD) was 24%; moderate-severe GVHD developed in 27%. Poor-risk disease characteristics, prior NA exposure, complete vs partial remission, and transplant characteristics were not independently associated with PFS. Hematopoietic cell transplantation-specific comorbidity index independently predicts PFS. PFS and OS were not impacted by having received NAs vs both NAs and chemoimmunotherapy, 1 vs ≥2 NAs, or ibrutinib vs venetoclax as the line of therapy immediately pre-alloHCT. AlloHCT remains a viable long-term disease control strategy that overcomes adverse CLL characteristics. Prior NAs do not appear to impact the safety of alloHCT, and survival outcomes are similar regardless of number of NAs received, prior chemoimmunotherapy exposure, or NA immediately preceding alloHCT. Decisions about proceeding to alloHCT should consider comorbidities and anticipated response to remaining therapeutic options.
引用
- Roeker LE, Dreger P, Brown JR, et al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020. PMID: 32841336. doi:10.1182/bloodadvances.2020001956
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。